title: [Optimal therapeutic concentration of tacrolimus in adult patients undergoing reduced-intensity cord blood transplantation].
abstract: To investigate the effectiveness and safety of GVHD prophylaxis using FK506 alone as a continuous infusion, 104 patients who underwent reduced-intensity cord blood transplantation were retrospectively reviewed. The respective incidence of acute GVHD was 25 grade 1(24. 1%), 19 grade2(18. 3%), 15 grade3(14. 4%), and 4 grade4(3. 8%), which are comparable to that in the literature. The incidences of grade 2 and greater acute GVHD were 32 out of 69(46. 4%)for those whose wholeblood concentration of FK506 werele ss than 13 ng/mL, whereas 6 out of 35(17. 1%)for those FK5 06 were greater than 13 ng/mL. The differenceies between above and below 13 ng/mL were statistically significant(p=0. 008). There were 19 cases(18. 3%)of renal dysfunction, although none required hemodialysis. There were only 4 patients who discontinued FK506, which further confirmed the safety of FK506 alone. Together with our previous report on the upper limit of FK506(17 ng/mL)and these results, we recommend the optimal serum concentration of FK506 to range from 13 to 17 ng/ mL.
authors.affiliation: Dept. of Pharmacy, Tokyo Metropolitan Geriatric Hospital.
authors.forename: Izumi
authors.initials: I
authors.lastname: Nasu
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Ito
authors.forename: Kanako
authors.initials: K
authors.lastname: Ino
authors.forename: Mayumi
authors.initials: M
authors.lastname: Minowa
authors.forename: Masako
authors.initials: M
authors.lastname: Furusawa
authors.forename: Yuri
authors.initials: Y
authors.lastname: Okuno
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Uchida
authors.forename: Kazuya
authors.initials: K
authors.lastname: Ishiwata
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Nakano
authors.forename: Masanori
authors.initials: M
authors.lastname: Tsuji
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Takagi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Naofumi
authors.initials: N
authors.lastname: Matsuno
authors.forename: Yuki
authors.initials: Y
authors.lastname: Mori
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Uchida
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Masuoka
authors.forename: Atsushi
authors.initials: A
authors.lastname: Wake
authors.forename: Shigeyoshi
authors.initials: S
authors.lastname: Makino
authors.forename: Shigesaburo
authors.initials: S
authors.lastname: Miyakoshi
authors.forename: Shuichi
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005312:Fetal Blood / Q000637:transplantation*; D006086:Graft vs Host Disease / Q000097:blood / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D016559:Tacrolimus